Danish diagnostics company in US merger  

DAKO to merge with US company Cytomation Inc.

Politiken Online reports that the Danish diagnostics company DAKO, partly owned by Novo, is to merge with the US company Cytomation Inc. which designs and produces high performance cell sorters and analysers. The new company, to be called DAKO Cytomation, will have a combined workforce of 1400 people and a turnover of DKK 1.4 billion (USD 168 million). If the merger goes ahead as planned, the company envisions flotation next year on either the Copenhagen Stock Exchange (KFX) or NASDAQ.


By combining the two companies' strengths with DAKO's worldwide sales network, it is hoped to create a platform for development and distribution of systems solutions for the growth markets in advanced cellular analysis. DAKO has 18 subsidiaries and distributors around the world, while Colorado-based Cytomation has sales and service offices in Germany and Australia.

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×